Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis.

Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Abstract Text:

B ,R Ceska,

Apolipoprotein E (apoE) is a plasma lipoprotein which plays a basic role in the degradation of particles rich in cholesterol and triglycerides. It is able to bind to LDL receptors, but also to receptors for chylomicron remnants. There are three major apoE isoforms, E2, E3, and E4. Their role in lipoprotein metabolism is related to their affinity for receptors. Allele E3 is predominant and apoE3 affects metabolism of lipoproteins in a standard way. When compared to allele E3, allele E2 is associated with lower LDL levels, whereas allele E4 with higher LDL levels. This has an impact on the progression of atherosclerosis. Allele E2 exhibits a protective role, whereas allele E4 is associated with a high risk factor. Lipoprotein(a) [Lp(a)] is a plasma lipoprotein, consisting of apolipoprotein(a), linked by a covalent bond with the LDL particle. Increased Lp(a) levels are associated with an increased incidence of diseases based on atherosclerosis, namely the ischemic heart disease. Another effect of Lp(a) is its competition with plasminogen, resulting in a decrease of fibrinolysis and thrombogenic activity. ApoE and Lp(a) are independent risk factors for premature development of atherosclerosis and therefore can be considered as candidate genes of premature atherosclerosis.

Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Publishing Authors By Initials

B ,R Ceska,

For similar proteins: protein isoforms research abstracts see: proteins: protein isoforms research

PUBMED ID PMID:

MEDLINE DATE:

Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Journal Published:

PUBLICATION TYPE: Review

Journal: Physiological research / Academia Scientiarum Bohe

VOLUME: 49 Suppl 1

Page Numbers: S63-9

Journal Abbreviation: Physiol Res

ISSN: 0862-8408

DAY: 2

MONTH: 04

YEAR: 2000

Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Information

Number of References: 31

LANGUAGE: eng

NlmUniqueID: 9112413

Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Keywords Mesh Terms:

KEYWORDS: Protein Isoforms

MESH TERMS: metabolism

Chemical & Substance for Abstract: Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Information

Substance Name: Protein Isoforms

Registry Number: 0

Grant and Affiliation Information for Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis.

AFFILIATION: Third Medical Department, First Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic. brohe@post.cz

Country: CZECH REPUBLIC

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Physiol Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Apolipoproteins and atherosclerosis Apolipoprotein E and apolipoproteina as candidate genes of premature development of atherosclerosis Related Publications

• Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis.
• Cholesterol lowering and the vessel wall: new insights and future perspectives.
• Clinical implications of the metabolic syndrome.
• Decrease in serum dehydroepiandrosterone level after fenofibrate treatment in males with hyperlipidemia.
• Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
• Leukocyte and endothelial adhesion molecules in patients with hypercholesterolemia: the effect of atorvastatin treatment.
• Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment.
• Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
• Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?
• Rosiglitazone in the prevention of diabetes and cardiovascular disease: Dream or reality?
• Serum leptin concentrations in patients with combined hyperlipidemia: relationship to serum lipids and lipoproteins.
• [In Process Citation]